Document Detail


Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
MedLine Citation:
PMID:  2195845     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study examined the effects of aminohydroxybutylidene bisphosphonate in 30 patients with Paget's disease of bone, administered as an intravenous infusion for 5 consecutive days. Treatment (5 mg IV daily) induced marked suppression of biochemical indices of disease activity. Urinary excretion of hydroxyproline fell to 50% of pretreatment values within 2 weeks and was followed by a similar, but later, decline in the serum activity of alkaline phosphatase. Disease activity remained suppressed throughout the 6 months of observation, and only 1 patients showed biochemical signs of an early relapse. Symptomatic improvement was noted in 27 of the 30 patients. Bone biopsies, undertaken in 10 patients, indicated no adverse effects on mineralization. Transient falls were noted in the total white cell count, particularly the lymphocyte and neutrophil fractions, and were associated with short-lived fever in 3 patients. We conclude that short courses of intravenous AHButBP provide a promising treatment for active Paget's disease of bone.
Authors:
D P O'Doherty; D R Bickerstaff; E V McCloskey; N A Hamdy; M N Beneton; S Harris; M Mian; J A Kanis
Related Documents :
1509065 - Postoperative diskitis: distinguishing early mr imaging findings from normal postoperat...
6404095 - Dna-flow cytometry of blood and bone marrow in chronic myelogenous leukemia.
10942925 - Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral...
10552095 - The use of bone scintigraphy to detect active hansen's disease in mutilated patients.
8734745 - Prospective evaluation of infrahisal second-degree av block induced by atrial pacing in...
3199465 - The percutaneous common femoral vein catheter for volume replacement in critically inju...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research     Volume:  5     ISSN:  0884-0431     ISO Abbreviation:  J. Bone Miner. Res.     Publication Date:  1990 May 
Date Detail:
Created Date:  1990-08-13     Completed Date:  1990-08-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8610640     Medline TA:  J Bone Miner Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  483-91     Citation Subset:  IM    
Affiliation:
Department of Human Metabolism and Clinical Biochemistry, University of Sheffield Medical School, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Alendronate
Bone Density / drug effects
Bone Resorption / drug therapy
Clinical Trials as Topic
Diphosphonates / administration & dosage,  adverse effects,  therapeutic use*
Female
Humans
Infusions, Intravenous
Leukopenia / chemically induced
Male
Middle Aged
Osteitis Deformans / blood,  drug therapy*,  physiopathology
Chemical
Reg. No./Substance:
0/Diphosphonates; 66376-36-1/Alendronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study.
Next Document:  Seasonal nature of birth of schizophrenic patients